

Published online: 12 October 2018

## **OPEN Author Correction: Impact of** hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer

Hai-Yuan Yang<sup>1</sup>, Ding Ma<sup>1</sup>, Yi-Rong Liu<sup>1</sup>, Xin Hu<sup>1</sup>, Jian Zhang<sup>2</sup>, Zhong-Hua Wang<sup>2</sup>, Gen-Hong Di<sup>1</sup>, Xi-Chun Hu<sup>2</sup> & Zhi-Ming Shao<sup>1</sup>

Correction to: Scientific Reports https://doi.org/10.1038/s41598-017-00663-1, published online 25 April 2017

In Figure 2 the subgroup order is incorrect.


HR+HER2+, trast+ HR-HER2+, trast-HR+HER2+, trast+ HR-HER2+, trast-

should read:

HR+HER2+, trast+ HR-HER2+, trast+ HR+HER2+, trast-HR-HER2+, trast-

The correct Figure appears below.

<sup>1</sup>Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. <sup>2</sup>Department of Medical oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Correspondence and requests for materials should be addressed to G.-H.D. (email: genhongdi@163.com)



**Figure 2.** Kaplan-Meier curves of overall survival (OS) in HER2-positive metastatic breast cancer (MBC) patients according to hormone receptor (HR) status and trastuzumab-containing palliative therapy (trast+/-).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>.

© The Author(s) 2018